The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 148-149

  Isidori, Alessandro ^a   Merli, Francesco ^b   Angrilli, Francesco ^c   Ferrara, Felicetto ^d   Alesiani, Francesco ^e   Visani, Giuseppe ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

^b Arcispedale ^*  (Italy)

^c SPIRITO SANTO HOSPITAL   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e Bartolomeo Eustacchio Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ARTICLE; DOSE RESPONSE; DRUG MECHANISM; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LYMPHOCYTE DEPLETION; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG COMBINATIONS; FEMALE; HUMANS; INCIDENCE; LYMPHOMA, B-CELL; MALE; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PREDNISOLONE; SURVIVAL RATE; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VINCRISTINE;

EID: 78651311755     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.525726     Document Type: Article

References (9)

1. Cheson BD. Infectious and immunosuppressive complications of purine analogs. J Clin Oncol 1995;13:2431-2448.
2. Morrison VA. Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2001;1:84-90.
3. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine and prednisone. Leuk Lymphoma 2010;51:797-801.
4. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496-502.
5. Kolstad A, Holte H, Fosså; A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007;92:139-140.
6. Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 2008;80:275-276.
7. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of NHL-B2 trial of the DSHNHL. Blood 2004;104: 634-641. (Pubitemid 38970554)
8. Tadmor T, McLaughlin P, Polliack A. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP 14: the price of a dose-dense regimen? Leuk Lymphoma 2010;51:737-738.
9. Katsuya H, Suzumiya J, Sasaki H, et al. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and predniso-lone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:1818-1823.